Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nintedanib dry powder inhaler - MannKind Corporation

Next Previous
X
Search
Drug Profile

Nintedanib dry powder inhaler - MannKind Corporation

Alternative Names: MNKD-201; nintedanib DPI - MannKind Corporation

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MannKind Corporation
  • Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Skin disorder therapies; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Lyn protein-tyrosine kinase inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Src-family kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 May 2024 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in USA (Inhalation) (NCT06532942)
  • 08 May 2024 US FDA approves IND application for Nintedanib dry powder inhaler for Idiopathic pulmonary fibrosis (In volunteers) before May 2024
  • 30 Apr 2024 MannKind Corporation plans a phase I trial for Idiopathic pulmonary fibrosis (In volunteers) in June 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top